Vorinostat potentiates CFZ-mediated DNA damage, apoptosis, and tumor growth suppression in an in vivo OCI-LY10 xenograft model. NIH-III nude mice were injected in the flank with (A) 10 × 106 OCI-LY10 cells or (B) 10 × 106 SUDHL4 cells and treated with the indicated doses CFZ with or without vorinostat twice weekly on days 1 and 2 as described in “Animal studies.” Tumor volumes were measured twice every week, and mean tumor volume was plotted against days of treatment. (C) Tumor samples were extracted from mice and lysed with lysis buffer followed by sonication. Western blotting was performed using the extracted proteins, which were then probed with the indicated primary antibodies. Each lane was loaded with 20 μg of protein; blots were subsequently stripped and reprobed with antibodies to tubulin to ensure equivalent loading and transfer. (D) Tumor samples were extracted after the 25th day of treatment and fixed to slides as described in “TUNEL assays of tissue sections.” TUNEL assays were performed on the fixed cells, which were also counterstained with 4,6-diamidino-2-phenylindole. Photomicrographs were obtained with an Olympus fluorescence microscope (original magnification ×20). (E) Weights of each mouse after various treatment regimens were monitored weekly, and the mean weight of each group was plotted against days of treatment.
